Immunogen, Inc.

NASDAQ:IMGN   4:00:00 PM EDT
5.19
+0.18 (+3.59%)
7:44:29 PM EDT: $5.20 +0.01 (+0.19%)
Other Pre-Announcement

Immunogen Reports Q3 Revenue Of $15.4 Mln

Published: 11/04/2022 10:44 GMT
Immunogen, Inc. (IMGN) - Immunogen Reports Recent Progress and Third Quarter 2022 Financial Results.
Launch Preparations Completed Ahead of November 28, 2022 PDUFA Date.
Immunogen - Initial Data From Phase 2 Cadenza Study Demonstrated Encouraging Activity & Favorable Tolerability of Pivekimab Sunirine in Frontline Bpdc.
Immunogen - Total Revenues Were $15.4 Million for Quarter Ended Sept 30, 2022 Compared to $9.2 Million for Quarter Ended September 30, 2021.
Qtrly Earnings per Share $0.31.
Q3 Earnings per Share View $-0.25, Revenue View $12.5 Million -- Refinitiv Ibes Data (analyst estimates).
Sees 2022 Revenues Between $80 Million and $90 Million.
Sees Cash and Cash Equivalents at December 31, 2022 to Be Between $230 Million and $240 Million in 2022.2022 Revenue Guidance Does Not Reflect Potential Product Sales From Mirvetuximab.
Expects That Its Current Cash, Combined With Anticipated Product and Collaboration Revenues, Will Fund Operations Into 2024.
FY2022 Earnings per Share View $-0.87, Revenue View $80.2 Million -- Refinitiv Ibes Data (analyst estimates).